ActiGraph's Response to Novel Coronavirus (COVID-19) - March 24th Update
Bayer-backed study looks at how patients’ perceive digital products in care, clinical trials
ActiGraph activity monitors and a mobile app from Clinical Ink are are at the heart of a newly announced pilot study backed by Bayer, according to a statement released today by ActiGraph. The ongoing study is evaluating how these digital products and a Bluetooth-enabled weight scale are perceived by patients, and the feasibility of implementing such devices in future clinical trials run by the pharmaceutical company.
Published date: April 12th, 2018
By: Dave Muoio, mobihealthnews.com